In this issue:

>> VivaGel^® BV launched in Asia

>> Fleurstat BVgel launched in NZ

>> DEP^® irinotecan phase 2 commences after positive phase 1 results 

>> SPL7013 against SARS-COV-2 (coronavirus)

>> Fleurstat BVgel ranks as #1 topical BV treatment

>> Okamoto adds 11 more Asian countries to  licence

>> US regulatory update

>> COVID-19: Starpharma’s operations continue with minimal disruption

>> DEP^® docetaxel, DEP^® cabazitaxel and DEP^® irinotecan 

>> DEP^® patient case studies

>> AstraZeneca’s DEP^® trial ongoing in the US & US$3 million milestone payment received

>> New DEP^® ADC programs

>> DEP^® pipeline targets multiple high-value areas

>> Other DEP^® programs

>> Outlook, recent news & events

Download: Shareholder Update May 2020 (pdf file, 606kb)